“Thanks for the opportunity to participate.  I found the evening very enjoyable & I was very impressed with the attendee list.”
2014-09-11T10:43:02+00:00
“Thanks for the opportunity to participate.  I found the evening very enjoyable & I was very impressed with the attendee list.”
“A cracking event!”
2014-09-11T10:44:04+00:00
“A cracking event!”

Bailey Fisher's Life Sciences & Digital Health events are content-rich, peer-to-peer discussion forums for senior sector leaders and investors hosted by Claire Button PhD, Director of Life Sciences and Digital Health at Bailey Fisher.

Next event

14 June 2017, 18:00 - 20:30
Cambridge

Dinner with discussion

Peer-to-peer dinner with discussion for CEOs in Life Sciences & Digital Health, on the topic of 'Structuring your board for transition'. Experts at the table are Mark Treherne & David Brown. This event is hosted by Bailey Fisher Executive Search in partnership with Silicon Valley Bank and Taylor Wessing. Full info >

Previous guest speakers

We have welcomed some truly inspirational speakers to our previous events.

Denise Scots-Knight, CEO & Co-founder – Mereo Biopharma

Denise has over 25 years experience in the biopharmaceutical industry, in R&D management and as a VC. In 1999 she joined Nomura and became MD after heading the life science investment team investing globally in biotech companies. She led the Phase4 Partners MBO from Nomura in 2010. Denise has served on many US and European private and public boards, including Idenix (until acquired by Merck for $3.85bn).

Vishal Gulati, Partner – Draper Esprit

Vishal is one of Europe’s leading digital healthcare investors. A Partner at Draper Esprit, one of the largest and most active VC firms in Europe, Vishal is a qualified physician and chairman of the Digital Health Forum. Over the last decade he has championed deals across areas including diagnostics, devices & biotech.

Richard Mason, Head of J&J Innovation London

An experienced entrepreneur, physician and business leader, Richard works to catalyse early innovations and discover opportunities for collaboration and investment across Johnson & Johnson’s global healthcare businesses. Prior to joining J&J Innovation, Richard was CEO at XO1 before the company was acquired in a J&J Innovation facilitated deal in 2015.

Cathy Prescott, Founder/Director – Biolatris Ltd

Cathy is Mentor to the Ignite Summer Business School Programme at the Centre for Entrepreneurial Learning (University of Cambridge); Senior Associate for the Masters in Bioscience Enterprise (University of Cambridge) & Visiting Professor at Kings College, London. Previously, Cathy chaired the UK National Stem Cell Network Advisory committee.

Melanie Lee, Founder & NED – NightstaRx

Melanie was Founding CEO and now NED of NightstaRx, a Syncona backed private biopharmaceutical company specialised in bringing sight improving treatments to patients with retinal dystrophies. Melanie is currently CSO of BTG plc, a fast growing Interventional Medicine company on the international stage with its HQ in London.

Wolf Reik, Head of Laboratory – Babraham Institute

Molecular biologist Wolf Reik is honorary Professor of Epigenetics at the University of Cambridge and Associate Faculty at the Wellcome Trust Sanger Institute, where he is a founding member of the Centre for Single Cell Genomics. He is a Fellow of the Academy of Medical Sciences and Fellow of the Royal Society.

Fiona Marshall, Executive VP & CSO – Sosei Group

Fiona was Founder & CSO of Heptares,a clinical-stage company creating novel medicines targeting G protein-coupled receptors (GPCRs), a superfamily of receptors linked to a wide range of human diseases. Heptares was acquired by Japanese biopharmaceutical giant Sosei Group in a $400m deal in 2015.

Peter Mercelis, Director Applied Technologies – 3D Systems Corporation

Peter is Co-founder of LayerWise, an innovative & award winning spin-out from the University of Leuven, active in metal Additive Manufacturing for industrial, dental and medical applications. Peter grew the company as MD to acquisition by 3D Systems Corporation in 2014.

Darrin Disley, CEO & President – Horizon Discovery

Darrin is a life scientist who has been involved in the start-up and growth of a many business ventures. In 2012, he was named Business Leader of the Year at the European Life Science Awards and in 2014 listed Horizon Discovery Group plc on the LSE AIM market achieving a placement of $113 million, an all-time record for a life science company on AIM.